Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.32 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8971467 | 1.00 | GABRR1 (0.36) | GABRR1LMNAGABBR2GABBR1 | |
| SCHEMBL285028 | 0.81 | — | — | |
| SCHEMBL497323 | 0.78 | — | — | |
| SCHEMBL5427480 | 0.76 | GABRR1 (0.31) | GABRR1LMNA | |
| SCHEMBL6901467 | 0.76 | GABRR1 (0.45) | GABRR1LMNAGABBR2GABBR1 | |
| SCHEMBL11795419 | 0.75 | — | — | |
| SCHEMBL7332947 | 0.72 | — | — | |
| SCHEMBL27820254 | 0.71 | — | — | |
| SCHEMBL381733 | 0.71 | — | — | |
| SCHEMBL8633356 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024050285-A2 | LEPTIN ANALOGS FOR TREATING OBESITY AND WEIGHT MANAGEMENT | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-03-07 | — | — | WO | disclosed |
| WO-2024030214-A2 | BRINP2-DERIVED PEPTIDE COMPOSITIONS FOR TREATING OBESITY AND WEIGHT MANAGEMENT | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-02-08 | — | — | WO | disclosed |
| US-20230192767-A1 | IL-2RGAMMA BINDING COMPOUNDS | MCMEEKIN, DERMOT (GB) | 2023-06-22 | — | — | US | disclosed |
| US-11548914-B2 | IL-2Rgamma binding compounds | MEDIKINE, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11390657-B2 | Peptide analogs | ADEPTHERA LLC (US) | 2022-07-19 | — | — | US | disclosed |
| EP-4023667-A1 | IL-2 RECEPTOR BINDING COMPOUNDS | Medikine, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| US-11358986-B2 | IL-2RBETA binding compounds | MEDIKINE, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| EP-3833679-A1 | IL-2 RECEPTOR BINDING COMPOUNDS | Medikine, Inc. (US) | 2021-06-16 | — | — | EP | disclosed |
| US-11034745-B2 | Superagonist polypeptide analogs of adrenomedullin and intermedin peptide hormones | ADEPTHERA LLC (US) | 2021-06-15 | — | — | US | disclosed |
| EP-3294752-B1 | PEPTIDE TREATMENT FOR INFLAMMATION AND FIBROSIS | UNIV CALIFORNIA (US) | 2020-11-04 | — | — | EP | disclosed |
| CN-1099613-A | Method and medical agent for diagnosis and/or therapy of arthritis | NIPPON PETROCHEMICALS CO LTD (JP) | 1995-03-08 | — | — | CN | disclosed |
| EP-0629409-A1 | Tetrapyrrole carboxylic acid derivatives for diagnosis and/or therapy of arthritis | NIPPON PETROCHEMICALS CO., LTD. (JP) | 1994-12-21 | — | — | EP | disclosed |
| US-5308861-A | Tetrapyrole compounds | NIPPON PETROCHEMICALS COMPANY, LIMITED (JP) | 1994-05-03 | — | — | US | disclosed |
| EP-0213272-B1 | NEW TETRAPYRROLE POLYAMINOMONOCARBOXYLIC ACID THERAPEUTIC AGENTS | Nippon Petrochemicals Co., Ltd. (JP) | 1992-09-09 | — | — | EP | disclosed |
| EP-0200218-B1 | TETRAPYRROLE THERAPEUTIC AGENTS | Nippon Petrochemicals Co., Ltd. (JP) | 1992-01-22 | — | — | EP | disclosed |
| US-4997639-A | Porphyrins | NIPPON PETROCHEMICALS COMPANY, LIMITED (JP) | 1991-03-05 | — | — | US | disclosed |
| EP-0213272-A2 | New tetrapyrrole polyaminomonocarboxylic acid therapeutic agents | Nippon Petrochemicals Co., Ltd. (JP) | 1987-03-11 | — | — | EP | disclosed |
| EP-0200218-A2 | Tetrapyrrole therapeutic agents | Nippon Petrochemicals Co., Ltd. (JP) | 1986-11-05 | — | — | EP | disclosed |
| US-4410513-A | Synthetic peptides having pituitary growth hormone releasing activity | BECKMAN INSTRUMENTS, INC. (US) | 1983-10-18 | — | — | US | disclosed |
| WO-1983002272-A1 | SYNTHETIC PEPTIDES HAVING PITUITARY GROWTH HORMONE RELEASING ACTIVITY | BECKMAN INSTRUMENTS INC (US) | 1983-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034745-B2 | Superagonist polypeptide analogs of adrenomedullin and intermedin peptide hormones | RAMP1, CALCRL, RAMP3 | GABRR1 2351/4885LMNA 1517/4885GABBR2 2718/4885 |
| US-11390657-B2 | Peptide analogs | RAMP1, RAMP3, RAMP2 | GABRR1 531/4885LMNA 3399/4885GABBR2 820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.